Sarepta Therapeutics (SRPT) Profit After Tax (2010 - 2026)
Sarepta Therapeutics (SRPT) posted quarterly Profit After Tax of $350.9 million for Q1 2026, up 178.4% year-over-year from $126.0 million in Q1 2025, and up 185.11% quarter-over-quarter from -$412.2 million in Q4 2025.
Sarepta Therapeutics (SRPT) Profit After Tax (2010 - 2026) Analysis & Trends
Sarepta Therapeutics' Profit After Tax history runs 17 years deep, the most recent figure standing at $350.9 million for Q1 2026.
- In Q1 2026, Profit After Tax rose 178.4% year-over-year to $350.9 million; the TTM figure through Mar 2026 stood at $85.0 million (up 134.2% YoY), while the FY2025 annual figure was -$713.4 million, down 403.27% from the prior year.
- Profit After Tax for Q1 2026 stood at $350.9 million, up from -$412.2 million in the prior quarter.
- The five-year high for Profit After Tax was $350.9 million in Q1 2026, with the low at -$516.8 million in Q1 2023.
- The 5-year median for Profit After Tax is -$40.9 million (2023), against an average of -$80.2 million.
- Peak annual rise in Profit After Tax reached 2947.86% in 2025, while the deepest fall reached 1338.98% in 2025.
- Sarepta Therapeutics' Profit After Tax stood at -$106.1 million in 2022, then jumped by 143.05% to $45.7 million in 2023, then surged by 248.37% to $159.0 million in 2024, then slumped by 359.18% to -$412.2 million in 2025, then soared by 185.11% to $350.9 million in 2026.
- Business Quant data shows SRPT's Profit After Tax at $350.9 million in Q1 2026, -$412.2 million in Q4 2025, and -$50.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 472.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,087.27 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -16.62 Mn |
| 10 | Sarepta Therapeutics | 1.91 Bn | 1.12 Bn | 251.87 Mn | -4.89 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -4.89 Mn |
| Mar 31, 2026 | 350.86 Mn |
| Dec 31, 2025 | -412.23 Mn |
| Sep 30, 2025 | -50.57 Mn |
| Jun 30, 2025 | 196.89 Mn |
| Mar 31, 2025 | -447.51 Mn |
| Dec 31, 2024 | 159.05 Mn |
| Sep 30, 2024 | 33.61 Mn |
| Jun 30, 2024 | 6.46 Mn |
| Mar 31, 2024 | 36.12 Mn |
| Dec 31, 2023 | 45.66 Mn |
| Sep 30, 2023 | -40.94 Mn |
| Jun 30, 2023 | -23.94 Mn |
| Mar 31, 2023 | -516.76 Mn |
| Dec 31, 2022 | -106.06 Mn |
| Sep 30, 2022 | -257.74 Mn |
| Jun 30, 2022 | -231.48 Mn |
| Mar 31, 2022 | -105.03 Mn |
| Dec 31, 2021 | -121.98 Mn |
| Sep 30, 2021 | -48.14 Mn |